NICM Health Research Institute, Western Sydney University, Penrith, Australia.
NICM Health Research Institute, Western Sydney University, Penrith, Australia; Translational Health Research Institute, Western Sydney University, Penrith, Australia.
J Obstet Gynaecol Can. 2020 Mar;42(3):256-261. doi: 10.1016/j.jogc.2019.08.033. Epub 2019 Nov 10.
This study sought to determine the prevalence, tolerability, and self-reported effectiveness of cannabis in women with endometriosis.
A cross-sectional online survey was conducted between October and December 2017. Recruitment targeted women with endometriosis through social media postings from endometriosis advocacy groups. Women aged 18 to 45, living in Australia, and with surgically confirmed endometriosis were eligible to participate. Survey questions investigated the types of self-management used, change in symptoms or medication use, costs, and adverse events.
A total of 484 responses were included for analysis, with 76% of the women reporting the use of general self-management strategies within the last 6 months. Of those using self-management, 13% reported using cannabis for symptom management. Self-reported effectiveness in pain reduction was high (7.6 of 10), with 56% also able to reduce pharmaceutical medications by at least half. Women reported the greatest improvements in sleep and in nausea and vomiting. Adverse effects were infrequent (10%) and minor.
Australian law currently requires legal medicinal cannabis use to follow specific, regulated pathways that limit prescription by this method; however, self-reported illicit use of cannabis remains relatively common in Australian women with endometriosis. Women report good efficacy of cannabis in reducing pain and other symptoms, with few adverse effects reported. Further clinical research is warranted to determine the effectiveness of cannabis in managing endometriosis symptoms. In locations where medicinal cannabis is more accessible, there remains a paucity of evidence for its clinical efficacy with endometriosis-associated symptoms.
本研究旨在确定子宫内膜异位症女性中使用大麻的流行率、耐受性和自我报告的有效性。
2017 年 10 月至 12 月期间进行了一项横断面在线调查。通过来自子宫内膜异位症倡导组织的社交媒体帖子，针对患有子宫内膜异位症的女性进行招募。年龄在 18 至 45 岁之间、居住在澳大利亚且经手术证实患有子宫内膜异位症的女性有资格参与。调查问题调查了自我管理所使用的类型、症状或药物使用的变化、成本和不良反应。
共纳入 484 份分析回复，其中 76%的女性报告在过去 6 个月内使用了一般自我管理策略。在使用自我管理的女性中，13%报告使用大麻来控制症状。自我报告的疼痛缓解效果很高（10 分制为 7.6 分），其中 56%的人还能将药物减少至少一半。女性报告睡眠、恶心和呕吐的改善最大。不良反应很少见（10%）且轻微。
目前澳大利亚法律要求合法医用大麻的使用必须遵循特定的、受监管的途径，限制了这种方法的处方；然而，在澳大利亚患有子宫内膜异位症的女性中，自我报告的非法使用大麻仍然相对普遍。女性报告大麻在减轻疼痛和其他症状方面具有良好的疗效，报告的不良反应很少。需要进一步的临床研究来确定大麻在管理子宫内膜异位症症状方面的有效性。在医用大麻更容易获得的地方，关于其治疗子宫内膜异位症相关症状的临床疗效的证据仍然很少。
